AI losses and some new leadership hint at a possible stock market rotation. Cisco fell late. Cathie Wood and Nancy pick ...

Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Magnus Tempus 360—a visionary initiative dedicated to forging new curatorial and collaborative pathways across the Mediterranean.

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate ...

Alphabet, UnitedHealth Group, Salesforce, Oracle, ServiceNow, Palo Alto Networks, and Tempus AI are the seven Healthcare ...

In conjunction with its better-than-expected sales growth in the second quarter, Tempus AI raised its sales outlook for this ...

In trading on the Nasdaq as of 1:17 p.m. Central, Tempus' stock price was $60.65, up 3.2% from the previous day's close.